A recent publication in the Journal of Clinical Endocrinology and Metabolism provides new data about the role of growth hormone (GH) in bone in Prader–Willi syndrome. The lack of positive effects of long-term GH therapy on BMD in young adults with Prader–Willi syndrome highlights the need to improve the transition from adolescent to adult health care.
